Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Marizyme Inc (QB) | MRZM | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.055 | 16:04:38 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.055 | 0.055 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.05 - 0.405 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.055 | USD |
Marizyme Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.33M | 43.42M | 12.02M | 233k | -38.17M | -0.82 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Marizyme (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRZM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0735 | 0.0735 | 0.053 | 0.0696826 | 4,193 | -0.0185 | -25.17% |
| 1 Month | 0.0551 | 0.095 | 0.053 | 0.0739499 | 10,043 | -0.0001 | -0.18% |
| 3 Months | 0.10 | 0.1339 | 0.053 | 0.0816939 | 7,024 | -0.045 | -45.00% |
| 6 Months | 0.19 | 0.19 | 0.053 | 0.0999654 | 7,969 | -0.135 | -71.05% |
| 1 Year | 0.1228 | 0.405 | 0.05 | 0.1674069 | 16,354 | -0.0678 | -55.21% |
| 3 Years | 1.75 | 3.25 | 0.05 | 0.5909975 | 7,947 | -1.70 | -96.86% |
| 5 Years | 1.10 | 4.48 | 0.05 | 0.7710081 | 5,468 | -1.05 | -95.00% |
Marizyme (QB) Description
| Marizyme is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes. Currently, we are focused on developing three medical technology products -- DuraGraft, MATLOCTM and Krillase -- each of which is backed by a portfolio of patented or patent-pending assets. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, therefore maintaining endothelial function and structure while improving clinical outcomes. MATLOC is a point-of-care, lab-on-chip digital screening and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment. Our Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health. |
